SK바이오사이언스 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by SK케미칼, was filed 27 Mar 2026.
SK바이오사이언스: what insiders have been doing
This page follows insider dealings at SK바이오사이언스 as filed with DART (FSS), a company from the Technology sector. Over the twelve months to 2 November 2026, 8 filings were filed, from 7 insiders.
Not one open-market sale was filed. On the buying side, 6 insiders reported 7 purchases totalling €116k. No amount is published for 6 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €116k by 김훈, published on 26 March 2026, equal to 0.0070% of the market capitalisation. Among those who bought: 3 senior executives and 1 chief executive.
The most recent open-market purchase was published on 27 March 2026, 227 days ago. Filings reach the DART (FSS) feed a median of 4 days after the trade. Until a filing is published, the market cannot know about the trade.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 8 filings here. Our records for SK바이오사이언스 go back to 2021, with 59 purchases and 5 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Basler Aktiengesellschaft and Lime Technologies AB (publ). These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -22.6%Entry ₩42,300 · Close 30 Oct 2026 ₩32,750
- -24.2%Entry ₩43,200 · Close 30 Oct 2026 ₩32,750
- +101.6%Entry ₩1,018,000 · Close at T+90 ₩2,052,000
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate SK바이오사이언스 Underperform (bearish), based on 5 analysts. Average price target: ₩36,200.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 73,483 sharesKRXDART:20260327001256Canonical exit: 21 Jun 2026 (T+90)
- 21,852 shares@ ₩9,154.000.0070% mcap100.0% of flowShareKRXDART:20260326000825Canonical exit: 22 Jun 2026 (T+90)
- 20 sharesKRXDART:20260224003078Canonical exit: 14 May 2026 (T+90)
- ●Executives0DART
- 11,273 sharesShareKRXDART:20260106000423Canonical exit: 6 Apr 2026 (T+90)
- 1,023 sharesShareKRXDART:20260106000436Canonical exit: 6 Apr 2026 (T+90)
- 21,852 sharesShareKRXDART:20251226000309Canonical exit: 26 Mar 2026 (T+90)
- 21,852 sharesShareKRXDART:20251215000355Canonical exit: 15 Mar 2026 (T+90)
- ●Executives0DART
- ShareKRXDART:20231219000230Canonical exit: 17 Mar 2024 (T+90)
- ShareKRXDART:20231219000226Canonical exit: 17 Mar 2024 (T+90)
- 377,684 sharesKRXDART:20231219000207
- ShareKRXDART:20230912000251Canonical exit: 5 Dec 2023 (T+90)
- ●Executives0DART
- ShareKRXDART:20220907000431Canonical exit: 6 Dec 2022 (T+90)
- ShareKRXDART:20220907000417Canonical exit: 6 Dec 2022 (T+90)
- ShareKRXDART:20220708000433Canonical exit: 6 Oct 2022 (T+90)
- ShareKRXDART:20220525000490Canonical exit: 23 Aug 2022 (T+90)
- ShareKRXDART:20220525000486Canonical exit: 23 Aug 2022 (T+90)
- ShareKRXDART:20220504000743Canonical exit: 2 Aug 2022 (T+90)
- ShareKRXDART:20220428000765Canonical exit: 27 Jul 2022 (T+90)
- ShareKRXDART:20220428000769Canonical exit: 27 Jul 2022 (T+90)
- ShareKRXDART:20220428000760Canonical exit: 27 Jul 2022 (T+90)
- ShareKRXDART:20220421000396Canonical exit: 20 Jul 2022 (T+90)
- ShareKRXDART:20220418000302Canonical exit: 17 Jul 2022 (T+90)
25 of 70 declarations
About SK바이오사이언스
SK Bioscience is a technology company listed on the XKRX. It focuses on the development of biopharmaceutical solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
